Royalty Pharma And Syndax Pharmaceuticals Enter Into $350 …
2 days ago · NEW YORK, NY, and WALTHAM, MA, November 4, 2024 - Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Royalty Pharma has entered into a $350 million synthetic royalty funding agreement with Syndax based on U.S. net sales of Niktimvo (axatilimab-csfr).
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 …
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib. Expected to fund Company through profitability; proforma cash approaching $800 million as of June 30. WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered ...
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 …
1 day ago · Under the terms of the agreement, Syndax received an upfront payment of $350 million in exchange for a 13.8% royalty on U.S. net sales of Niktimvo.
Syndax agrees funding with Royalty Pharma for Niktimvo US sales
17 hours ago · Syndax has received $350m upfront in return for a 13.8% royalty on Niktimvo’s net US sales. Royalty payments to Royalty Pharma will cease once they reach 2.35 times the initial amount. Syndax’s financial and legal advisors respectively were Goldman Sachs & Co and Cooley. Gibson, Dunn & Crutcher, and Dechert advised Royalty Pharma.
Syndax strikes $350M deal with Royalty Pharma for Niktimvo
9 hours ago · In exchange for the $350 million upfront, Syndax will pay a 13.8% royalty on U.S. sales of Niktimvo. The deal expires after Royalty gains 2.35 times its investment.
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 …
1 day ago · WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million ...
Syndax Reports Third Quarter 2024 Financial Results and Provides ...
1 day ago · The Company announced a $350 million royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo. Under the agreement, Syndax received $350 million in exchange for a 13.8% royalty on U.S. net sales of Niktimvo. Royalty payments to Royalty Pharma will cease upon reaching a multiple …
Syndax and Royalty Pharma sign $350m royalty funding …
1 day ago · Biopharmaceutical company Syndax Pharmaceuticals and Royalty Pharma have announced a $350m synthetic royalty agreement based on US net sales of Niktimvo (axatilimab-csfr). Under the agreement, Syndax Pharmaceuticals received a $350m upfront payment in exchange for a royalty of 13.8% on the net sales of Niktimvo in the US.
RPRX - Royalty Pharma and Syndax Pharmaceuticals Enter Into...
The recent $350 million royalty funding agreement between Royalty Pharma (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) marks a strategic milestone that investors should closely consider. This partnership aims to bolster the development and market entry of Niktimvo, a promising first-in-class product targeting chronic graft-versus ...
Syndax Pharmaceuticals Secures $350 Million Synthetic Royalty …
Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo™ (axatilimab-csfr). "We expect this transaction to fund us through profitability, while ensuring that we continue to participate in the profits from Niktimvo and retain the ...
- Some results have been removed